Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Non-Current Deffered Revenue (2024 - 2025)

Historic Non-Current Deffered Revenue for Prime Medicine (PRME) over the last 2 years, with Q3 2025 value amounting to $59.8 million.

  • Prime Medicine's Non-Current Deffered Revenue fell 461.05% to $59.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.8 million, marking a year-over-year decrease of 461.05%. This contributed to the annual value of $63.2 million for FY2024, which is N/A changed from last year.
  • Per Prime Medicine's latest filing, its Non-Current Deffered Revenue stood at $59.8 million for Q3 2025, which was down 461.05% from $59.6 million recorded in Q2 2025.
  • Prime Medicine's 5-year Non-Current Deffered Revenue high stood at $63.2 million for Q4 2024, and its period low was $59.6 million during Q2 2025.